Dieser Anti-ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper ist ein Humanized Monoklonal Antikörper zur Detektion von ErbB2/Her2 (Trastuzumab Biosimilar) in FACS und in vivo. Geeignet für Human.
Produktnummer ABIN7795084
Kurzübersicht für Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper (ABIN7795084)
Target
ErbB2/Her2 (Trastuzumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
Expressionssystem
Mammalian cells
Verwendungszweck
Trastuzumab Biosimilar, N297A Mutant
Produktmerkmale
Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.